The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $65 and keeps a Buy rating on the shares following FDA ...

Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $58 from $57 and keeps an Overweight rating on the shares. The firm says Dawnzera was approved by the FDA on time with a ...

Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema ...

Major developments in health include the U.S. Supreme Court's decision to allow cuts to NIH grants under Trump, the famine ...

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...